Related Experiment Video
Updated: Jan 23, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
364
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony1,2,3, Ruby Yun-Ju Huang4,5,6
1Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Cancer Research
|July 2, 2017
Summary
The receptor tyrosine kinase AXL drives cancer progression and drug resistance by promoting epithelial-mesenchymal transition (EMT). Inhibiting AXL may reverse EMT and resensitize tumors to therapy, necessitating patient stratification for targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The receptor tyrosine kinase (RTK) AXL is implicated in epithelial-mesenchymal transition (EMT), enhancing cancer cell survival, invasion, and metastasis.
- AXL signaling confers an aggressive phenotype and drug resistance by directly influencing the mesenchymal state.
- Recent findings reveal EMT-induced rewiring of kinase signaling nodes, facilitating AXL cross-talk and sustained signaling through ERK and PI3K pathways.
Purpose of the Study:
- To elucidate the molecular mechanisms regulating the interplay between the kinome and EMT.
- To highlight the reciprocal control between AXL signaling and the EMT state in oncogenesis.
- To review the therapeutic potential of AXL inhibition for developing novel cancer treatments.
Main Methods:
- Literature review of studies on AXL, EMT, and cancer signaling pathways.
- Analysis of molecular mechanisms underlying AXL-EMT crosstalk.
- Evaluation of therapeutic strategies targeting AXL.
Main Results:
- AXL plays a crucial role in EMT-mediated oncogenesis, promoting aggressive cancer phenotypes.
- AXL signaling contributes to resistance against various cancer therapies.
- AXL inhibition has demonstrated potential in reversing EMT and resensitizing cancer cells to treatments.
Conclusions:
- Understanding the AXL-EMT axis is critical for developing targeted cancer therapies.
- AXL inhibition represents a promising therapeutic strategy for overcoming drug resistance in various cancers.
- Patient stratification based on AXL dependence is essential for optimizing treatment outcomes.
More Related Videos
Related Concept Videos
02:03Xylem and Transpiration-driven Transport of Resources
26.4K
The xylem of vascular plants distributes water and dissolved minerals that are taken up by the roots to the rest of the plant. The cells that transport xylem sap are dead upon maturity, and the movement of xylem sap is a passive process.
26.4K
02:18Cancer
53.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.8K
02:57Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
01:27ATP Driven Pumps I: An Overview
9.7K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
9.7K
01:34ATP Driven Pumps II: P-type Pumps
6.2K
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
6.2K
01:30ATP Driven Pumps III: V-type Pumps
4.7K
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
4.7K